After a significant decline in its hepatitis C sales in 2016, Gilead Sciences Inc. is splitting its product sales guidance for 2017 into two categories – separating out the HCV franchise from the rest of its business –conceding that HCV sales will continue to decline this year and it is difficult to pinpoint the degree of that trend.
Gilead revealed during its fourth quarter and full-year 2016 earnings call Feb. 7 that sales of its HCV portfolio – Sovaldi (sofosbuvir), Harvoni (sofosbuvir/ledipasvir) and Epclusa (sofosbuvir/velpatasvir) – declined 35% worldwide during the fourth quarter and 22% for the full year